Avenciguat clinical trials

Studies by the year they started

14 studies that test it; most in 2017 (4)

Who runs them

Industry 14 · Other 0

Boehringer Ingelheim (14)

Often tested with

Tested in the same studies.

Esomeprazole (1)

Studies

Open first, then newest update. How each study uses avenciguat is read from its arms, and is right about nine times in ten.

Testing it · 14

• A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis SymptomsCompletedPhase 2Boehringer IngelheimNCT05559580Written as Avenciguat (BI 685509)
• A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)TerminatedPhase 2Boehringer IngelheimNCT05161481Written as Avenciguat (BI 685509)
• A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver ProblemsTerminatedPhase 1Boehringer IngelheimNCT06272058Written as Avenciguat (BI 685509)
• A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the BellyTerminatedPhase 2Boehringer IngelheimNCT06082843Written as Avenciguat
• A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney DiseaseCompletedPhase 2Boehringer IngelheimNCT04736628Written as Avenciguat
• A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney DiseaseCompletedPhase 2Boehringer IngelheimNCT04750577Written as BI 685509
• A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the BloodCompletedPhase 1Boehringer IngelheimNCT06193811Written as Avenciguat (BI 685509) (intended commercial formulation (iCF))
• A Study in Healthy Men to Test How BI 685509 is Processed in the BodyCompletedPhase 1Boehringer IngelheimNCT05515328Written as BI 685509 formulation 3
• A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver ProblemsCompletedPhase 1Boehringer IngelheimNCT03842761Written as BI 685509
• This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)CompletedPhase 1Boehringer IngelheimNCT03165227Written as BI 685509
• This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are ToleratedCompletedPhase 1Boehringer IngelheimNCT03259464Written as BI 685509
• Safety and Tolerability of BI 685509 in Healthy SubjectsCompletedPhase 1Boehringer IngelheimNCT03116906Written as BI 685509
• Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food EffectCompletedPhase 1Boehringer IngelheimNCT03116893Written as BI 685509 After Standardised Breakfast
• Investigation of Single Rising Doses of BI 685509CompletedPhase 1Boehringer IngelheimNCT02694354Written as BI 685509

Codes

What other systems call avenciguat · ClinicalTrials.gg INT018676

• UNII (FDA) ZA7KTB4PSPAVENCIGUATConfirmed FDA, Wikidata
• Wikidata Q123914013avenciguatConfirmed FDA, Wikidata
• NCI Thesaurus C203196AvenciguatOne source FDA
• DrugBank DB18882One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.